



1FW

Electronic Filing System (EFS) Data


Electronic Patent Application Submission

USPTO Use Only

EFS ID: 92039
Application ID: 10652864 
Title of Invention: Therapeutic applications of
noncovalent dimerizing
antibodies
First Named Inventor: Heinz Kohler
Domestic/Foreign Application: Domestic Application
Filing Date: 2003-08-29
Effective Receipt Date: 2005-09-05
Submission Type: BIO Sequence Filing
Filing Type:
Confirmation number: 1487
Attorney Docket Number: 200-019

Total Fees Authorized:

Digital Certificate Holder: cn=James H Meadows,ou=Registered Attorneys,ou=Patent and
Trademark Office,ou=Department of Commerce,o=U.S. Government,c=US
Certificate Message Digest: 2683860b35ebd63cf0376e04cce1e15fac865b19



TRANSMITTAL

Electronic Version v1.1
Stylesheet Version v1.1.0

Title of Invention	Therapeutic applications of noncovalent dimerizing antibodies	
Application Number:	10/652864	
Date:	2003-08-29	
First Named Applicant:	Heinz Kohler	
Confirmation Number:	1487	
Attorney Docket Number:	200-019	
<p>I hereby certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.</p> <p>I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.</p>		
Submitted by:	Elec. Sign.	Sign. Capacity
James H. Meadows Registered Number: 33965	/jhmeadows/	Attorney



Documents being submitted	Files
us-bio-seq-trans	200-019seqlist-usbios.xml
	us-bio-seq-trans.dtd
	us-bio-seq-trans.xsl
sequence-listing	seqlist.txt
Comments	
Applicant understands the previous CRF submission may be defective. Accordingly, a replacement sequence listing is submitted.	